Navigation Links
Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
Date:2/3/2009

EMERYVILLE, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received a quarterly royalty payment of approximately $1.5 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of Alzheimer's disease. Under an exclusive marketing agreement, NTI currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The company recently terminated development of its most advanced product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials for evaluation as a new drug to treat acute ischemic stroke. NTI has an early-stage development program for Alzheimer's disease and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug which has recently completed a Phase 3 trial for brain swelling.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies Announces Suspension of Viprinex Development
2. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
3. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
4. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
5. Neurobiological Technologies Sets Date for First Quarter Financial Results
6. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
7. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
8. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
10. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
11. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... have made great strides in saving China,s endangered national ... over 65 giant panda reserves that have been established ... just 1596 pandas remain in the wild. , ... save the panda by improving genetic diversity, avoid inbreeding ... how are these high-profile programs doing so far? , ...
(Date:7/23/2014)... at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), the Vienna University ... have succeeded in embedding nearly perfect semiconductor crystals ... of producing hybrid nanowires, very fast and multi-functional ... chip in the future. The research results will ... . , Nano-optoelectronics are considered the cornerstone of ...
(Date:7/23/2014)... , July 23, 2014  AuraSense Therapeutics, ... as gene regulatory and immunotherapeutic agents, announced ... joined AuraSense Therapeutics, executive leadership team as ... Prior to joining AuraSense Therapeutics, Mr. ... Financial Officer of Cellular Dynamics International Inc., ...
(Date:7/23/2014)... Last year, Formedix celebrated its partnership with ... data management solutions for clinical trials. The company launched ... data capture (EDC) and clinical data management. Formedix, a ... added TrialMaster to its Transform for EDC product line. ... TrialMaster, is being released this week, in response to ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3
... PAREXEL International (NASDAQ: PRXL ), a ... H. von Rickenbach, Chairman and Chief Executive Officer of ... Massachusetts Biotechnology Council (MassBio) CRO/CMO Symposium , to ... Waltham, Massachusetts. The symposium, organized by the MassBio Contract ...
... Study results published today in the   New - ...   show that 3-year graft survival is significantly greater in all ...   Kidney Transporter compared to those stored in a traditional box ... [1]   The graft survival difference at three years was ...
... Graduate Institute (KGI) has been selected by the Council ... Foundation to administer the Professional Science Master,s (PSM) Affiliation ... quality standards for PSM programs across the country. ... look forward to providing leadership for this important degree ...
Cached Biology Technology:PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium 2PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium 3PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium 4PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium 5Machine Preservation Significantly Improves Kidney Transplant Survival Over 3 Years Compared to Traditional box of ice 2Machine Preservation Significantly Improves Kidney Transplant Survival Over 3 Years Compared to Traditional box of ice 3KGI Selected to Administer PSM Affiliation Process 2
(Date:7/23/2014)... Networking in personalized cancer medicine, (the WIN consortium), recently ... Thomas Jefferson University will be one of its ... prestigious group in the Tri-State Area. The goal of ... medicine to the patient by forging collaborations between partners ... in the WIN consortium means Jefferson cancer patients will ...
(Date:7/23/2014)... temperature around the world by 2050, according to one ... Climate Change (IPCC), may be advantageous to the physiology ... growth of forage plants such as Stylosanthes capitata ... tropical countries such as Brazil., The conclusion is from ... of Biology at the Ribeiro Preto Faculty of Philosophy, ...
(Date:7/23/2014)... HOLE, MA -- What do mollusks, starfish, and ... marine habitat, they are all calcifiersorganisms that use ... skeletons and shells for stability and protection. , ... , published by the Marine Biological Laboratory, addresses ... composition changes worldwide. , As atmospheric carbon dioxide ...
Breaking Biology News(10 mins):New partnership brings more personalized cancer treatment to Philadelphia 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Calcification in changing oceans explored in special issue of The Biological Bulletin 2
... Fingerprints mark us out as individuals and leave telltale ... touch, but what are fingerprints really for? According to ... and tree-climbing koalas have fingerprints and some South American ... everyone presumed that fingerprints are there to help us ...
... in a remote region of the Russian mountains a previously ... discovered. Lead Scientist Professor Hans Cornelissen and his Russian-Dutch team ... The root belongs to the small alpine plant Corydalis conorhiza ... upward through layers of snow. Given this novel behaviour, the ...
... edition of the BBVA Foundation Frontiers of Knowledge ... under the presidency of the Spanish Minister of ... Foundation President, Francisco Gonzlez. The public at the ... scientific community and high-level government institutions alongside personalities ...
Cached Biology News:Urban myth disproved: Fingerprints do not improve grip friction 2Newly discovered snow roots are 'evolutionary phenomenon' 2The BBVA Foundation presents its Frontiers of Knowledge Awards 2
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... DW4 liquid handling system from Molecular Devices ... in one instrument. The system handles a ... plate washing96-, 384- and 1536-welland is the ... DW4 has been optimized to dispense from ...
... exist between the various commercial and lab-prepared ... used, the length and GC content of ... manufacturing protocol employed all influence the optimal ... With all the different variables to consider, ...
... ICS-1500 system provides excellent performance with ... electrolytic suppression, and column heater all ... outstanding sensitivity and stability. The vacuum ... for trace-level work. Operate in manual ...
Biology Products: